Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
July 17, 2024 08:00 ET
|
Longeveron
Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.
Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease
July 15, 2024 08:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
July 10, 2024 07:30 ET
|
Longeveron
Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
Diadem Appoints Michael Rasche as Chief Executive Officer
July 10, 2024 07:00 ET
|
Diadem SpA
Industry veteran Michael Rasche named CEO of Diadem, a leader in developing blood tests for the early prediction of progression to Alzheimer’s disease.
Neha Motwani Elected to Longeveron® Board of Directors
July 09, 2024 09:00 ET
|
Longeveron
Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
July 08, 2024 09:00 ET
|
Longeveron
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Pacific Software Inc. Obtaining Quotes for the Manufacturing Cycle for Scientifically Tested Medical Food Cocktail Focused on Memory Health
June 28, 2024 18:43 ET
|
Pacific Software Inc.
Pacific Software Inc. expands into memory health with SuppleMEM AD™ and A.L.Z. Defense™. USA and Mexico distribution is planned for Q3 2024.
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
June 17, 2024 09:00 ET
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
June 10, 2024 09:00 ET
|
Longeveron
Longeveron to Present at the Emerging Growth Virtual Conference
Longeveron® Announces Contract Development and Manufacturing Business and First Contract
June 03, 2024 09:00 ET
|
Longeveron
Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.